QuickView for phosphothreonine residue binding (biogroup)

1. L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (1 of 2)
2. L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
3. L1000 CMAP - Embryonic stem HUES3 cells treated with small molecule perturbagens
4. L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
5. L1000 CMAP - Skeletal muscle SKL.C cells treated with small molecule perturbagens

1. Dimerization, but not phosphothreonine binding, is conserved between the forkhead-associated domains…
2. Regulation of budding yeast mating-type switching donor preference by the FHA domain of Fkh1.
3. Structure and interactions of the cytoplasmic domain of the Yersinia type III secretion protein YscD…
4. Gene expression regulation through 14-3-3 interactions with histones and HDACs.
5. The FHA-containing protein GarA acts as a phosphorylation-dependent molecular switch in mycobacteria…

There were no clinical trials for phosphothreonine residue binding